Gastric cancer is a common malignancy worldwide, with a particularly high incidence in China. Most patients are diagnosed at an unresectable, locally advanced or metastatic stage. Approximately 85% of patients have HER2-negative disease. Although first-line immunotherapy combined with chemotherapy has significantly improved outcomes for patients with advanced HER2-negative gastric cancer, the benefits of this approach are beginning to reach a plateau, highlighting the urgent need for new treatment strategies.Gastric cancer is a common malignancy worldwide, with a particularly high incidence in China. Most patients are diagnosed at an unresectable, locally advanced or metastatic stage. Approximately 85% of patients have HER2-negative disease. Although first-line immunotherapy combined with chemotherapy has significantly improved outcomes for patients with advanced HER2-negative gastric cancer, the benefits of this approach are beginning to reach a plateau, highlighting the urgent need for new treatment strategies.

Advances in modern oncology have introduced a range of groundbreaking treatment approaches for lung cancer, making it one of the fastest-evolving solid tumors. To help clinicians gain a deeper and more comprehensive understanding of major developments in this field, Oncology Frontier has partnered with Professor Hua Zhong, Director of the Department of Pulmonary and Critical Care Medicine at Shanghai Chest Hospital, and Professor Baohui Han to launch a series of clinical updates titled “Zhong” Voice, “Hui” Insights. Through expert interpretations of high-quality clinical studies in lung cancer, the series aims to promote improvements in clinical practice and patient care.

Autumn skies over Beijing welcomed distinguished experts from across the field. From September 11 to 13, 2026, the 20th Gastric Cancer Academic Conference of the Gastric Cancer Committee of the Chinese Anti-Cancer Association (CGCC 2026) was held in Beijing. Under the theme “Inheritance, Innovation, Standardization, and Improvement,” the conference continued its founding mission of providing a multidisciplinary academic exchange platform for the gastric cancer community. Through keynote presentations, thematic sessions, international exchange forums, clinical research discussions, and multidisciplinary team (MDT) sessions, the meeting focused on the latest advances in gastric cancer research, promoted standardized diagnosis and treatment, fostered interdisciplinary integration, and advanced translational research bridging basic science and clinical practice.

Patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) inevitably face the challenge of acquired resistance after first-line treatment with third-generation EGFR tyrosine kinase inhibitors (TKIs). Currently, there is no universally established standard of care following resistance. Options such as platinum-based chemotherapy, EGFR-TKI combination regimens, antibody–drug conjugates (ADCs), and novel targeted agents remain under investigation. For these patients, balancing antitumor activity, intracranial disease control, and long-term treatment tolerability remains a major clinical challenge.

Numerous anti-HER2 antibody–drug conjugates (ADCs) are now available in clinical practice. Based on their payload mechanisms, they can be broadly classified into topoisomerase I inhibitor (TOP1i)-based ADCs and microtubule inhibitor-based ADCs. These two classes differ in their mechanisms of action, resistance profiles, and risks of cross-resistance. Bodutuzumab, a microtubule inhibitor-based ADC featuring the novel payload Duostatin-5 and a distinctive mechanism of action, has demonstrated differentiated advantages in patients who have progressed after tyrosine kinase inhibitor (TKI) therapy or who have received or developed resistance to TOP1i-based ADCs. In the KL166-III-06 study, a head-to-head comparison of bodutuzumab with trastuzumab emtansine (T-DM1) also demonstrated significant improvements in progression-free survival (PFS) and objective response rate (ORR), with adverse events that were manageable, preventable, and reversible.

From October 16 to 18, 2026, the 5th West Lake Gynecologic Oncology Conference, the 2026 Academic Annual Meeting of the Gynecologic Oncology Committee of the Zhejiang Anti-Cancer Association, and the 2026 Academic Conference of the Cervical Cancer Integrated Prevention and Screening Committee of the Chinese Anti-Cancer Association were held in Hangzhou, China. The events were organized by the Zhejiang Anti-Cancer Association and undertaken by Zhejiang Cancer Hospital and the Cervical Cancer Integrated Prevention and Screening Committee of the Chinese Anti-Cancer Association. The meetings focused on basic and clinical research in gynecologic oncology and advances in surgical techniques, with discussions addressing key challenges in precision and individualized treatment.

Hepatocellular carcinoma (HCC) complicated by portal vein tumor thrombus (PVTT) is associated with a very poor prognosis, limited treatment options, and substantial clinical challenges. Immunotherapy combined with targeted therapy has become an important first-line treatment approach for unresectable HCC. Although the triplet strategy of hepatic arterial infusion chemotherapy (HAIC) combined with immunotherapy and targeted therapy has demonstrated promising antitumor activity in small phase II studies, large-scale real-world evidence confirming its survival benefits has been lacking.

From September 16 to 19, 2026, the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), jointly organized by CSCO and the Beijing Xisike Clinical Oncology Research Foundation, was held in Jinan, Shandong Province, China. The meeting brought together oncology experts from China and around the world to address real-world clinical challenges, share cutting-edge advances, and engage in discussions on novel drug development and optimization of diagnostic and treatment strategies, fostering in-depth academic exchange between the international oncology community.

The 29th Chinese Society of Clinical Oncology (CSCO) Academic Annual Meeting was held in Jinan from September 16 to 19, 2026. Under the theme “Upholding Standards and Advancing Digital and Intelligent Innovation,” the meeting showcased China's achievements in oncology innovation, reflecting the country's transition from following global advances to keeping pace with—and increasingly leading—the field. In the treatment of RAS wild-type metastatic colorectal cancer (mCRC), the introduction of China's domestically developed, fully human anti-EGFR antibody panitumumab N01 is significantly reshaping the anti-EGFR treatment landscape. During the meeting, Professor Yanhong Deng of the Sixth Affiliated Hospital of Sun Yat-sen University spoke with Oncology Frontier about the evolution of first-line treatment for advanced RAS wild-type colorectal cancer, the clinical value of panitumumab N01, and the future of China's innovative medicines.

The 29th CSCO Academic Annual Meeting, jointly organized by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was grandly opened in Jinan, Shandong Province, from September 17 to 19, 2026. With the theme “Upholding Standards and Advancing Digital and Intelligent Innovation,” the annual meeting continued CSCO's longstanding mission of bringing together renowned oncology experts and scholars from around the world to share cutting-edge research findings and clinical experience. The meeting is expected to further advance cancer diagnosis and treatment in China and worldwide.